Please ensure Javascript is enabled for purposes of website accessibility
Brian Orelli

Brian Orelli


Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Recent articles


Should Investors Be Worried About Shorts Attacking Clover Health?

It's too early to know who's right.


Here's Why Bristol Myers Squibb Is Making A Mistake With Its Cash

Boosting its pipeline could have a bigger effect on the earnings line.


Pfizer Has Gotten Better at Developing Drugs. Here's Why

The pharma giant is setting itself up for success, although a little luck also helps.


There's More to Merck's New 'Bean Counter' CEO Than First Appears

The former chief financial officer has some experience in operations as well.


Bristol Myers Is Taking Full Advantage of its Celgene Acquisition

The acquisition is adding to both top- and bottom-line growth.


Here's Why Editas Medicine Dropped Today

After a huge run-up in valuation, investors are a little spooked.


What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?

The biotech is looking for late-sage drugs to fuel future growth.


Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared

The biotech's revenue and earnings growth were better than the reported results.

Doctor patient heart face masks

Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

The biotech will get $345 million through an upfront payment and equity investment.

Vaccination 5

Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Manufacturing capacity is increasing dramatically despite the short-term issue.


Coronavirus Vaccine Allergic Reactions: Red Flag or Par for the Course?

For now, they're a statistical anomaly.


Can Coronavirus Antibodies Overcome Their Obstacles?

Issues with timing, delivery, and manufacturing make the treatments less promising.


Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial

Investors should be cautious until the biotech has data from a controlled study.


Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

The lack of a quick rejection could be a good sign for the drug's prospects.


Can COVID Vaccine Makers Benefit From the Biden Administration?

More doses mean more profits, but the companies and the government need to come to a deal.


Novavax Gets the Job Done With its COVID Vaccine

It may be behind, but the biotech's clinical trial data looked good.


Johnson & Johnson's Coronavirus Vaccine Data Isn't as Bad as It First Appears

The company had to worry about more coronavirus variants than the first two authorized vaccines.


Vaccines Are Still Protecting Against the Coronavirus Variants (for Now)

The vaccine makers are still hedging their bets.


How Will Biden's Executive Orders Affect Your Healthcare Stocks?

The decisions could have both short- and long-term implications.

Investor excited

Here's Why Seagen Jumped Higher Today

The rumor mill took hold in late-day trading.